Clinical Trial Update: A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating AB-205 in lymphoma patients undergoing autologous hematopoietic cell transplantation was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• AB-205 (AB-205)

Snippet

Sponsor: Angiocrine Bioscience | Conditions: Hodgkin Lymphoma, Non Hodgkin Lymphoma | Phase 3 | Status: TERMINATED